SkinHealth Systems Inc. (NASDAQ:SKIN) experienced a dramatic rally on Tuesday, with shares surging approximately 50% in midday trading on volume more than 50 times the 65-day average. The sharp move followed the company's announcement that its SkinStylus microneedling device had received FDA clearance for treating periorbital wrinkles, but market participants quickly focused on the stock's price level relative to Nasdaq's listing requirements.
The stock traded as high as $1.17 during the session, briefly crossing the $1 threshold that is critical for the company's continued listing on the Nasdaq exchange. SkinHealth had previously disclosed in a May filing that Nasdaq had warned the stock had closed below $1 for 30 consecutive sessions through May 7, triggering a cure period that expires on November 4. To regain compliance, the company needs to maintain a closing price of at least $1 for a minimum of 10 consecutive trading days, though Nasdaq may require 20 days.
While the intraday move above $1 is encouraging, the real test will come at the close. Only closing prices matter for Nasdaq compliance purposes, making Tuesday's closing price—and the sustainability of any gains—the key metric for investors to watch. The stock had closed at $0.7549 on Monday, so a sustained move above $1 would represent a significant step toward resolving the listing issue.
The FDA clearance itself is a positive development for SkinHealth, expanding the approved use of the SkinStylus device to include periorbital wrinkles in all Fitzpatrick skin types. Whitney Cypes, the company's chief brand and clinical innovation officer, described the clearance as an "important milestone." Dr. Glynis Ablon, who led the clinical study, noted that SkinStylus produced "clinically meaningful improvements" in the targeted wrinkles.
However, there is a notable discrepancy in the age indications between the company's announcement and the FDA's official records. SkinHealth's press release stated the device is cleared for adults aged 22 and older, while the FDA's indication form specifies adults aged 34 and older for the periorbital wrinkle use. The FDA's 510(k) database shows a "Substantially Equivalent" decision dated February 19, with the web page last updated on July 6.
The broader context for SkinHealth remains challenging. The company reported first-quarter net sales of $64.9 million, a decline of 6.7% from the prior year. Delivery systems sold fell to 746 from 862, though the active install base grew to 36,419 from 35,014. Consumables revenue dropped to $46.4 million from $49.4 million, and delivery systems sales declined to $18.5 million from $20.2 million. On a positive note, adjusted EBITDA improved to $8.5 million from $7.3 million, and the net loss narrowed to $6.6 million from $10.1 million.
The company holds $204.4 million in cash, cash equivalents, and restricted cash as of March 31, down from $232.7 million at year-end. Convertible senior notes stand at $102.9 million current and $241.3 million long-term, providing some financial flexibility but not directly addressing the Nasdaq listing issue.
Tuesday's trading activity effectively circled two key dates: July 7, when the FDA clearance was announced, and November 4, the end of the Nasdaq cure period. With the FDA decision actually dating back to February, the clearance itself is not entirely fresh news, but the market's reaction underscores the high stakes for SkinHealth as it works to meet listing requirements while navigating a soft sales environment.
